Changeflow GovPing Pharma & Drug Safety Multivalent Peptide Conjugates for Intra-Articu...
Routine Rule Added Final

Multivalent Peptide Conjugates for Intra-Articular Joint Inflammation Treatment

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12599663B2 to VALITOR, INC. on April 14, 2026. The patent covers multivalent peptide-polymer conjugates designed for sustained intra-articular treatment of joint inflammation, with 23 claims.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued patent US12599663B2 to VALITOR, INC. for multivalent peptide-polymer conjugates designed for sustained intra-articular treatment of joint inflammation. The patent, which covers 23 claims including composition and method of use, was granted under CPC classifications related to therapeutic peptides, polymer conjugates, and intra-articular delivery systems. Filing date was March 8, 2019, under application number 16977636.\n\nFor pharmaceutical and biotechnology companies, this patent establishes exclusive intellectual property rights for VALITOR in the area of sustained-release peptide conjugates for joint inflammation treatment. Competitors developing similar intra-articular peptide-polymer conjugate technologies for arthritis and joint disorders should review this patent for freedom-to-operate considerations and potential licensing opportunities.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation

Grant US12599663B2 Kind: B2 Apr 14, 2026

Assignee

VALITOR, INC.

Inventors

Wesley M. Jackson, Mavish Mahomed, Livia W. Brier, Kevin E. Healy

Abstract

The present disclosure is directed to peptide-polymer conjugates, and to their use in treating intra-articular diseases or disorders.

CPC Classifications

A61K 39/3955 A61K 31/728 A61K 47/22 A61K 47/61 A61K 47/68 A61K 2039/505 A61K 9/0024 A61K 38/00 A61K 9/0019 A61K 2039/54 A61K 2039/545 A61P 19/02 C07K 2317/92 C07K 2317/94 C07K 16/241 C07K 16/245 A61L 27/20 A61L 27/50 A61L 27/54 A61L 2300/256 A61L 2300/426 A61L 2300/252 A61L 2300/432 A61L 2400/06 C08L 5/08

Filing Date

2019-03-08

Application No.

16977636

Claims

23

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599663B2

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent issuance Intellectual property protection Therapeutic peptide development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!